{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T12:40:01Z","timestamp":1716208801461},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T00:00:00Z","timestamp":1385164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00108-013-3331-7","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T08:28:56Z","timestamp":1385454536000},"page":"1450-1458","source":"Crossref","is-referenced-by-count":0,"title":["Was ist gesichert in der Therapie der axialen Spondyloarthritis?","What is ascertained in the therapy of axial spondyloarthritis?"],"prefix":"10.1007","volume":"54","author":[{"given":"J.","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,23]]},"reference":[{"key":"3331_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"Braun","year":"2007","unstructured":"Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379\u20131390","journal-title":"Lancet"},{"key":"3331_CR2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Heijde D van\u00a0der, Landew\u00e9 R et\u00a0al (2009) The development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (part\u00a0II): validation and final selection. Ann Rheum Dis 68:777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"3331_CR3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","volume":"Res","author":"Kiltz","year":"2012","unstructured":"Kiltz U, Baraliakos X, Karakostas P et\u00a0al (2012) Do patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 64:1415\u20131422","journal-title":"Arthritis Care"},{"key":"3331_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molimm.2013.06.013","volume":"57","author":"Robinson","year":"2013","unstructured":"Robinson PC, Brown MA (2013) Genetics of ankylosing spondylitis. Mol Immunol 57:2\u201311","journal-title":"Mol Immunol"},{"key":"3331_CR5","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Haibel H, Listing J et\u00a0al (2012) Baseline radiographic damage, elevated acute phase reactants and cigarette smoking status predict radiographic progression in the spine in early axial spondyloarthritis. Arthritis Rheum 64:1388\u20131398","journal-title":"Arthritis Rheum"},{"key":"3331_CR6","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Berg R van den, Braun J, Heijde D van der (2012) Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 51:1378\u20131387","DOI":"10.1093\/rheumatology\/kes026"},{"key":"3331_CR7","doi-asserted-by":"crossref","unstructured":"Kiltz U, Sieper J, Braun J (2013) ASAS\/EULAR recommendations for the management of ankylosing spondylitis: evaluation of the 2010 update in the German-speaking area. Z\u00a0Rheumatol 72:71\u201380","DOI":"10.1007\/s00393-012-1071-z"},{"key":"3331_CR8","doi-asserted-by":"crossref","unstructured":"Kiltz U, Sieper J, Braun J (2013) ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis: evaluation of the 2010 update in the German-speaking area. Z\u00a0Rheumatol 72:81\u201388","DOI":"10.1007\/s00393-012-1089-2"},{"key":"3331_CR9","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde DV (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase\u00a0III trial. Arthritis Rheum 58:3402\u20133412","journal-title":"Arthritis Rheum"},{"key":"3331_CR10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"Braun","year":"2011","unstructured":"Braun J, Horst-Bruinsma IE van der, Huang F et\u00a0al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: a randomized, double-blind study (ASCEND Trial). Arthritis Rheum 63:1543\u20131551","journal-title":"Arthritis Rheum"},{"key":"3331_CR11","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"Wanders","year":"2005","unstructured":"Wanders A, Heijde DV, Landew\u00e9 R et\u00a0al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756\u20131765","journal-title":"Arthritis Rheum"},{"key":"3331_CR12","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H et\u00a0al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71:1616\u20131622","journal-title":"Ann Rheum Dis"},{"key":"3331_CR13","doi-asserted-by":"crossref","unstructured":"Haibel H, Fendler C, Listing J et\u00a0al (2013) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis (im Druck)","DOI":"10.1136\/annrheumdis-2012-eular.2237"},{"key":"3331_CR14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"Braun","year":"1995","unstructured":"Braun J, Bollow M, Neure L et\u00a0al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499\u2013505","journal-title":"Arthritis Rheum"},{"key":"3331_CR15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","volume":"43","author":"Brandt","year":"2000","unstructured":"Brandt J, Haibel H, Cornely D et\u00a0al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346\u20131352","journal-title":"Arthritis Rheum"},{"key":"3331_CR16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J et\u00a0al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"3331_CR17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC et\u00a0al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60:946\u2013954","journal-title":"Arthritis Rheum"},{"key":"3331_CR18","doi-asserted-by":"crossref","unstructured":"Dougados M, Braun J, Szanto S et\u00a0al (2012) Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxford) 51:1687\u20131696","DOI":"10.1093\/rheumatology\/kes125"},{"key":"3331_CR19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/ard.2009.121533","volume":"69","author":"Dougados","year":"2010","unstructured":"Dougados M, Combe B, Braun J et\u00a0al (2010) A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 69:1430\u20131435","journal-title":"Ann Rheum Dis"},{"key":"3331_CR20","first-page":"672","volume":"29","author":"Heldmann","year":"2011","unstructured":"Heldmann F, Brandt J, Horst-Bruinsma IE van\u00a0der et\u00a0al (2011) The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 29:672\u2013680","journal-title":"Clin Exp Rheumatol"},{"key":"3331_CR21","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Listing J, Fritz C et\u00a0al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8\u00a0years \u2013 early clinical response predicts long-term outcome. Rheumatology (Oxford) 50:1690\u20131999","DOI":"10.1093\/rheumatology\/ker194"},{"key":"3331_CR22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/ar1750","volume":"7","author":"Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J et\u00a0al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3\u00a0years of continuous treatment with infliximab. Arthritis Res Ther 7:113","journal-title":"Arthritis Res Ther"},{"key":"3331_CR23","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT et\u00a0al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460\u20131468","journal-title":"JAMA"},{"key":"3331_CR24","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"Rudwaleit","year":"2007","unstructured":"Rudwaleit M, Schwarzlose S, Hilgert ES et\u00a0al (2007) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67:1276\u20131281","journal-title":"Ann Rheum Dis"},{"key":"3331_CR25","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","volume":"72","author":"Furst","year":"2013","unstructured":"Furst DE, Keystone EC, So AK et\u00a0al (2013) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 72(Suppl\u00a02):ii2\u2013ii34","journal-title":"Ann Rheum Dis"},{"key":"3331_CR26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S et\u00a0al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72:1605\u20131612","journal-title":"Ann Rheum Dis"},{"key":"3331_CR27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","volume":"71","author":"Braun","year":"2012","unstructured":"Braun J, Baraliakos X, Hermann KG et\u00a0al (2012) Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study. Ann Rheum Dis 71:878\u2013884","journal-title":"Ann Rheum Dis"},{"key":"3331_CR28","doi-asserted-by":"crossref","unstructured":"Braun J, Baraliakos X, Hermann KG et\u00a0al (2013) The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4\u00a0years of the GO-RAISE trial. Ann Rheum Dis (im Druck)","DOI":"10.1136\/annrheumdis-2012-203075"},{"key":"3331_CR29","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ et\u00a0al (2013) The impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65:2645\u20132654","journal-title":"Arthritis Rheum"},{"key":"3331_CR30","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Haibel H, Listing J et\u00a0al (2013) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8\u00a0years in patients with ankylosing spondylitis. Ann Rheum Dis (im Druck)","DOI":"10.1136\/annrheumdis-2012-202698"},{"key":"3331_CR31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"Linden","year":"1984","unstructured":"Linden S\u00a0van der, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum\u00a027:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"3331_CR32","unstructured":"Heijde\u00a0D van der, Bellamy N, Calin A et\u00a0al (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J\u00a0Rheumatol 24:2225\u20132229"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-013-3331-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3331-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T11:58:29Z","timestamp":1716206309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-013-3331-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,23]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3331"],"URL":"https:\/\/doi.org\/10.1007\/s00108-013-3331-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,23]]}}}